Capital Viii, Llc Vivo Capi... Net Worth

The estimated Net Worth of Capital Viii, Llc Vivo Capi... is at least $14.9 Million dollars as of 20 July 2018. Capital Capi owns over 353,180 units of Crinetics Pharmaceuticals Inc stock worth over $14,935,674 and over the last 6 years Capital sold CRNX stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Capital Capi CRNX stock SEC Form 4 insiders trading

Capital has made over 1 trades of the Crinetics Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Capital bought 353,180 units of CRNX stock worth $6,576,212 on 20 July 2018.

The largest trade Capital's ever made was buying 353,180 units of Crinetics Pharmaceuticals Inc stock on 20 July 2018 worth over $6,576,212. On average, Capital trades about 353,180 units every 0 days since 2018. As of 20 July 2018 Capital still owns at least 294,357 units of Crinetics Pharmaceuticals Inc stock.

You can see the complete history of Capital Capi stock trades at the bottom of the page.

What's Capital Capi's mailing address?

Capital's mailing address filed with the SEC is 505 Hamilton Ave #200, Palo Alto, CA 94301, USA.

Insiders trading at Crinetics Pharmaceuticals Inc

Over the last 6 years, insiders at Crinetics Pharmaceuticals Inc have traded over $52,514,606 worth of Crinetics Pharmaceuticals Inc stock and bought 3,613,259 units worth $62,800,483 . The most active insiders traders include Advisors Llcperceptive Life..., Jack Nielsen, and Capital Viii, Llc Vivo Capi.... On average, Crinetics Pharmaceuticals Inc executives and independent directors trade stock every 20 days with the average trade being worth of $3,116,248. The most recent stock trade was executed by Stephen F. Betz on 26 August 2024, trading 3,000 units of CRNX stock currently worth $159,570.

What does Crinetics Pharmaceuticals Inc do?

neuropeptide receptor targeted therapeutics for the treatment of endocrine diseases and cancers. we are driven by a passion for drug-hunting and tempered by a post-recession startup culture. our goal is to create new therapeutics that can make a meaningful difference in the lives of our patients.

Complete history of Capital Capi stock trades at Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals Inc executives and stock owners

Crinetics Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• R. Scott Struthers,
  President, Chief Executive Officer, Director
• Alan Krasner,
  Chief Medical Officer
• Marc Wilson,
  Chief Financial Officer
• Dr. R. Scott Struthers Ph.D.,
  Founder, Pres, CEO & Director
• Dr. Ajay Madan DABT, Ph.D., D.A.B.T.,
  Chief Devel. Officer
• Marc J. C. Wilson,
  CFO & Sec.
• Stephanie Okey,
  Independent Director
• Wendall Wierenga,
  Independent Chairman of the Board
• Matthew Fust,
  Independent Director
• Jeff E. Knight,
  Chief Operating Officer
• Stephen Kaldor,
  Independent Director
• Weston Nichols,
  Independent Director
• Peter Trainer,
  Vice President - Clinical Endocrinology
• Camille Bedrosian,
  Independent Director
• Adriana Cabre,
  Vice President of Human Resources
• Ajay Madan,
  Chief Development Officer
• Chris Robillard M.B.A.,
  Chief Bus. Officer
• James Hassard,
  Chief Commercial Officer
• Dr. Alan S. Krasner M.D.,
  Chief Medical Officer
• Adriana Cabre M.B.A.,
  Chief HR Officer
• Kevin Capps,
  Head of Intellectual Property
• Dr. Alan S. Krasner,
  Chief Medical Officer
• Garlan Adams,
  Gen. Counsel
• Dr. Stephen F. Betz Ph.D.,
  Founder & Chief Scientific Officer
• Dr. Yun-Fei Zhu,
  Founder & VP of Chemistry
• Jeff E. Knight,
  Chief Operating Officer
• Advisors Llcperceptive Life...,
  
• Capital Viii, Llc Vivo Capi...,
  
• Venture Capital V, L.P.Vers...,
  
• Capital Viii, Llc Vivo Capi...,
  
• Venture Capital V, L.P.Vers...,
  
• Capital Viii, Llc Vivo Capi...,
  
• James Hassard,
  Chief Commercial Officer
• Jack Nielsen,
  Director
• Coelho Rogerio Vivaldi,
  
• Dana Pizzuti,
  Chief Med and Dev Officer
• Stephen F. Betz,
  Chief Scientific Officer
• Caren Deardorf,